Loading company…
UCB China develops medicines for neurological, autoimmune, respiratory, and tumor diseases.
Founded in 2006 in Shanghai, UCB China develops medicines for central nervous system, autoimmune, allergy and respiratory, and tumor diseases. It has offices in Beijing, Chengdu, and Guangzhou, and a production base in Zhuhai. Its brands include Keppra, Vimpat, Neupro, Zytec, and Xyzal. In August 2024, Mubadala Investment Company and CBC Group announced an agreement to acquire UCB China for USD 680 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in